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2ABSTRACT
Aberrations in the Hedgehog signaling pathway are responsible for a broad range of human 
cancers, yet only a subset rely on the activity of the clinical target, Smoothened 
(Smo).  Emerging cases of cancers that are insensitive to Smo-targeting drugs demand new 
therapeutic targets and agents for inhibition.  As such, we sought to pursue a recently discovered 
connection between the Hedgehog pathway transcription factors, the Gli oncogenes, and protein 
kinase C (PKC) isozymes.  Here, we report our assessment of a structurally diverse library of 
PKC effectors for their influence on Gli function.  Using cell lines that employ distinct 
mechanisms of Gli activation up- and downstream of Smo, we identify a PKC effector that acts 
as a nanomolar Gli antagonist downstream of Smo through a MEK-independent mechanism. 
This agent provides a unique tool to illuminate crosstalk between PKC isozymes and Hh 
signaling and new opportunities for therapeutic intervention in Hh pathway-dependent cancers.
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3Aberrant activity of the Gli transcription factors (Gli1, Gli2, and Gli3) within the 
Hedgehog (Hh) signaling pathway is a driving factor in several major human cancers.1,2,3,4,5  
While the Hh pathway serves essential roles during embryogenesis,6 reactivation of Gli activity 
in adult tissue is oncogenic.7,8,9  In canonical Hh signaling, the pathway is stimulated by binding 
of the secreted Hh morphogen to its transmembrane receptor Patched1 (Ptch1).10  This event 
releases the negative regulation of Ptch1 on the seven-transmembrane receptor Smoothened 
(Smo), transducing the signal across the membrane and triggering activation of the Gli 
transcription factors (Figure 1A).  Alternatively, non-canonical Hh signaling, in which Gli 
transcription is activated independently of the Hh-Ptch1-Smo axis,11,12,13 can be initiated at 
multiple points upstream, downstream, or epistatic to Smo.  Studies have traced transcriptional 
Gli amplification or posttranslational Gli regulation to cross-talk with a number of signaling 
pathways, including MEK/ERK,14 PI3K/AKT,15 TGF-β,16 mTOR/S6K1,17 and others.  Despite 
the diversity of Gli activation mechanisms, all FDA-approved drugs target the same site within 
Smo.  Hence, no therapies are available for Gli tumorigenesis that is stimulated downstream of 
Smo or is resistant to these molecules.  Utilizing chemical biology to elucidate cellular 
mechanisms that govern Gli regulation is needed to identify next-generation drugs for Gli-driven 
cancers. 18,19
Several studies have identified events that intersect with Gli activity, including reports 
that show a regulatory role for protein kinase C (PKC) isozymes.20,21,22,23,24,25,26,27  Importantly, 
PKC isozymes are proposed to interact with Hh signaling at different points during pathway 
activation.  For example, PKC/ directly phosphorylates Gli to upregulate Hh target genes,23 
whereas PKC has been shown to regulate Gli activity via the mitogen-activated protein (MAP) 
kinase (MEK/ERK) pathway.25,28  PKC  possesses pro-apoptotic effects in numerous cancers;26 
however, the effects of this isozyme on Gli are duration- and cell type-dependent.25,27  While 
crosstalk between the Hh pathway and PKC provides opportunities for small molecule 
intervention in both canonical and non-canonical Gli regulation, the activities of individual PKC 
effectors remain poorly understood, and only a limited set of PKC agonists have been employed 
in studies of Hh signaling.29,30,31  In this report, we identify a small molecule PKC effector that 
exhibits nanomolar inhibition of Gli activity downstream of Smo.  These studies provide a 
valuable tool to investigate the PKC-Gli axis and new avenues for therapeutic development.
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4PKCs, like other families of kinases, contain a conserved catalytic domain responsible for 
phosphate transfer.32,33,34  In addition, specific classes of PKCs are susceptible to small molecule 
regulation through endogenous diacylglycerol- (DAG-) and/or calcium binding regulatory 
domains.  Affinity for DAG and/or calcium can be further enhanced by phospholipid mediators 
such as phosphatidylserine.  The ten human PKC isoforms are divided into three categories 
according to their sensitivity to DAG and interaction with calcium (Figure 1B).  While 
conventional PKCs (   ) are sensitive to calcium and DAG, novel PKCs (   ) are 
sensitive to DAG but insensitive to calcium.  By contrast, atypical PKCs ( ) lack both 
calcium and C1 regulatory domains and are thus insensitive to both.
Figure 1. The Hedgehog signaling pathway and PKC. (A) Mechanism of Hedgehog pathway 
activation. Binding of Hh to Ptch1 releases suppression of Smo, whereupon activated Smo 
promotes dissociation of Gli proteins from Sufu.  Gli proteins are converted into their active 
forms (GliA), which translocate to the nucleus and induce Hh pathway target gene expression.  
Activation of MEK/ERK signaling is independently able to regulate the formation of GliA.  
PKCs are reported to act both directly on proteins in the Hh pathway and MAP kinases.  (Hh: 
Hedgehog, Ptch1: Patched 1, Smo: Smoothened, Gli: Glioma-associated oncogene, Sufu: 
Supressor of Fused, MAP: Mitogen-Activated Protein kinase, MEK: mitogen-activated protein 
kinase kinase; PKC: Protein Kinase C).  (B) Regulation of PKC isozymes. Comparison of the 
conventional, novel, and atypical classes of the PKC family showing the regulatory domain 
cofactors required for enzyme activation. (C) RNA-seq analysis of PKC isozymes in NIH-3T3 
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5cells after 30 h treatment with SAG (200 nM) or control (DMSO).  PKC isozymes from each 
class are expressed in NIH-3T3 cells at significant levels, which are unaffected by SAG 
treatment.  Mean count and fold change for the Hh pathway target genes Gli1, Ptch1, Pgm5, and 
Angtpl4 are shown for comparison. Differential expression was analyzed using DESeq2 with 
false discovery rate (FDR)-corrected p-value < 0.01. Biological triplicates were analyzed for 
each condition.
To identify a suitable cell-based model for evaluating PKC effectors, we first assessed the 
expression levels of various PKC isozymes in NIH-3T3 mouse embryonic fibroblasts (MEFs) 
using RNA-seq (Figure 1C).  Five PKC isoforms were observed at significant levels: PKC 
(conventional), PKC (conventional) PKC (novel), PKC (novel) and PKC (atypical); 
therefore, PKCs from each class were represented.  RNA-seq analysis in the presence of the Smo 
agonist SAG (Smoothened AGonist, 200 nM) demonstrated that expression of these isozymes 
did not change significantly upon Smo activation (Figure 1C).
To advance the potential of PKC effectors as Gli antagonists, we sought to define small 
molecule structures that could target specific aspects of Gli regulation within Hh-signaling 
cells.35  While the structural characteristics of each PKC class are well established, selective 
activation of PKC isozymes remains an unmet challenge.36  Hence, as opposed to classification 
based on PKC isozyme targets, PKC effectors are classified by the structural domains to which 
they bind.32  Regulatory domain modulators are a diverse collection of small molecules that 
influence PKC cellular localization, phosphorylation, and/or degradation.37,38,39,40  These agents 
can modify the activity of conventional and novel PKC isozymes, which possess a DAG-binding 
site in the C1 regulatory domain.  By contrast, kinase domain inhibitors, which have variable 
isozyme selectivity, are available for all three PKC classes.36  While each class of PKC effector 
has been studied in a multitude of biological contexts, only a handful of reports have studied 
PKC activity in Hh signaling.21,22,23,24,25,26,27  In addition, although numerous molecules including 
natural products, peptides, and synthetic agents can interact with PKCs, structural features within 
a given scaffold often lead to idiosyncratic isozyme preferences, potencies, and mechanisms of 
action.31,41  Because distinct PKC isozymes are emerging as critical regulators of Hh signaling, 
we sought to intercept Hh activity with specific PKC modulators.  Given the untapped diversity 
of these agents, we established a compound library encompassing three types of PKC effectors: 
(1) DAG-based lipids, (2) regulatory domain activators of the C1-binding site, and (3) selective 
and unselective inhibitors of the catalytic domain (Figure S1).  
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6Figure 2.  Evaluation of PKC effectors in Shh-LIGHT2 cells treated with 200 nM SAG.  (A) 
Comparison of compound potency versus magnitude of inhibition of Gli-driven luciferase. y–
axis: relative Gli-driven luciferase activity at 1.5 μM dose of each compound; x–axis: half 
maximal inhibitory concentration (IC50) for each compound.  Compounds: Vismodegib (grey 
circle), regulatory domain C1-binding site activators (blue circles), DAG-based lipid activators 
(green circles), and catalytic domain inhibitors (red circles). (B) Structures of Vismodegib and 
1–5 with compound potency and Gli-driven luciferase reporter activity in the presence of 200 
nM SAG and 1.5 µM of each compound. For A and B, Gli luciferase is calculated relative to Gli-
driven luciferase activity induced by 200 nM SAG (100%).  All values are the mean of n > 3 
biological replicates ± s.d.
We examined the effect of this structurally diverse library of PKC modulators on Gli- 
activity in Shh-LIGHT2 cells, an NIH-3T3-derived cell line stably transfected with a Gli-
dependent firefly luciferase reporter and a TK-driven Renilla luciferase control reporter for 
normalization.42   This cell line provides a well-established first assay to identify agents with 
nanomolar potency and/or a significant inhibition of Gli-driven luciferase activity initiated at 
Smo (Figure 2).  In each assay, SAG (200 nM) was co-administered to induce transcriptional Gli 
activity.  After a 30 h exposure to SAG and each PKC effector, normalized Gli-driven luciferase 
activity was measured and compared to SAG alone as a control.  Each compound was evaluated 
at a concentration of 1.5 M to determine level of Gli-driven luciferase inhibition (y–axis, Figure 
2A).  The half-maximal inhibitory concentration (x–axis, Figure 2A) for each agent was 
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7evaluated in individual dose-response experiments.  As a reference, the clinical Smo inhibitor 
Vismodegib (grey circle, Figure 2A) was also evaluated.30,31,43,44
PKC effectors from each domain-targeting group showed a range of inhibitory effects on 
Gli-driven luciferase activity (Figure S1, Table S1, and Figure S3).  Kinase domain inhibitors 
selective for conventional PKCs (Gö-6976) or atypical PKCs (myristoylated pseudosubstrate 
inhibitor and PKC-9) displayed minimal differences versus control (red circles, Figure 2A).   
Likewise, DAG-based lipids caused mild inhibition of Gli-driven luciferase activity at 
micromolar to near-micromolar concentrations (green circles, Figure 2A).  
Most significantly, the class of C1-binding site regulatory domain PKC activators 
consisted of compounds that strongly inhibited Gli-driven luciferase activity at nanomolar to 
near-nanomolar concentrations: TPPB (1), indolactam V (2), phorbol 12-myristate 13-acetate 
(PMA) (3), prostratin (4), and ceramide (5) (blue circles, Figure 2A).  Dipeptide 145 was the most 
potent compound investigated, showing almost complete suppression Gli-driven luciferase 
activity at double-digit nanomolar concentrations (IC50 = 20 ± 7 nM, Figure 2B).  This effect was 
comparable to that of Vismodegib, demonstrating that PKC effectors can act at therapeutically 
relevant concentrations.   Significantly, 1 is unique among these compounds as a neuroprotective 
agent38,39,46,47 without significant tumorigenic activity,36 suggesting it as a lead for therapeutic 
development.
The regulatory domain activator and established tumor-promoter 348 also showed 
nanomolar inhibition of Gli-driven luciferase activity in this cell type. The structurally related 
but non-tumor promoting 449 displayed a similar level of inhibition to 3 but reduced potency.37,50 
While initial reports have suggested that 3 functions to positively regulate Gli,25 subsequent 
studies have identified an alternative mechanism of Gli antagonism via PKCδ26  These 
conflicting observations may arise from differences in the time course of these studies, which 
can influence the dominant mechanism by which these agents act on PKC (Figure S2).
While clinical inhibitors have been successful at treating Gli-driven cancers initiated at or 
upstream of Smo, an increasing number of human cancers are recognized as originating from 
Smo-independent Gli activity.51,52 An elegant report by Toftgård and coworkers has 
demonstrated that the effector 3 can block Gli activity initiated downstream of Smo in MEFs.27  
To examine the potential for PKC modulators to influence Smo-independent Gli-driven 
luciferase activity, we evaluated our five most potent inhibitors in Sufu-KO-LIGHT cells.53,54  
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8Sufu-KO-LIGHT cells lack the Hh pathway component Sufu, a direct negative regulator of the 
Gli transcription factors, and thus exhibit constitutive Gli activity arising downstream of Smo. 
As in Shh-LIGHT2 cells, Sufu-KO-LIGHT cells express a stably integrated Gli-driven firefly 
luciferase reporter; in this assay, Gli-driven luciferase signal is normalized to cell viability.
Figure 3.  Analysis of lead compounds in Sufu-KO-LIGHT cells.  (A) Dose-response curves 
for Vismodegib and 1 in Sufu-KO-LIGHT cells and Shh-LIGHT2 cells stimulated with 200 nM 
SAG.  (B) Relative Gli-driven luciferase activity at 1.5 μM dose of Vismodegib, GANT, or 1–5 
in Sufu-KO-LIGHT cells. (C) Half maximal inhibitory concentration (IC50, nM) and percent Gli-
driven luciferase activity relative to control at 1.5 μM dose of Vismodegib, GANT, or 1–5 in 
Sufu-KO-LIGHT cells. For A and B, Gli luciferase is calculated relative to Gli-driven luciferase 
activity induced by 200 nM SAG in Shh-LIGHT2 cells (100%) or DMSO in Sufu-KO-LIGHT 
cells (100%).  All values are the mean of n > 3 biological replicates ± s.d.
Examination of 1–5 in Sufu-KO-LIGHT cells revealed that compounds 1, 2, 3, and 4 
retained potent effects on Gli activity.  As anticipated, the potency and maximum inhibition by 
the Smo inhibitor Vismodegib decreased by more than two orders of magnitude in these cells as 
compared to Shh-LIGHT2 cells (22% inhibition at 1.5 μM, Figure 3A, Table S2, and Figure S3), 
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9(IC50 > 5 M, Figure 3C).  By contrast, GANT-61, a downstream inhibitor of Gli,35 maintained a 
potency of IC50 = 2.2 ± 0.2 M and the ability to significantly inhibit Gli activity (Figure 3B and 
3C).  Of the PKC effectors, 5 lost three orders of magnitude in potency, which might reflect a 
direct effect of this lipid on the function of Smo.
Figure 4. Characterization of Gli inhibition in diverse cell types and on Gli-driven 
luciferase activity in the presence of a MEK inhibitor. (A) Gli1 mRNA levels in Shh-LIGHT2 
cells treated with 200 nM SAG and 1 at the concentrations indicated for 30 h.  (B) Gli1 mRNA 
levels in Sufu-KO-LIGHT cells treated with 1 at the concentrations indicated for 30 h.  In A and 
B, fold change is calculated relative to levels of B2M RNA using the ΔΔCt method. (C) Dose-
response curves for 1 and Vismodegib in C3H10T1/2 cells.  Alkaline phosphatase activity (ALP) 
is calculated relative to Gli-driven ALP activity induced by 200 nM SAG (100%). (D) Dose-
response curves for growth inhibition by 1 and Vismodegib in ASZ001 mBCC cells treated at 
the concentrations indicated for 48 h, measured using the CellTiter assay.  Viability is calculated 
relative to DMSO (100%).  (E) Relative Gli-driven luciferase inhibition in Shh-LIGHT2 cells by 
1 (1.5 µM) in the presence of SAG (200 nM) and MEK inhibitor CI-1040 (6, 100 nM). (F) 
Relative Gli-driven luciferase inhibition in Sufu-KO-LIGHT cells by 1 (1.5 µM) in the presence 
of MEK inhibitor 6 (100 nM). For E and F, Gli luciferase is calculated relative to Gli-driven 
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10
luciferase activity induced by 200 nM SAG in Shh-LIGHT2 cells (100%) or DMSO in Sufu-KO-
LIGHT cells (100%).  All values are the mean of n > 3 biological replicates ± s.d.
The most potent inhibitor in Shh-LIGHT2 cells, 1, suppressed both hSHH-N and SAG 
activation (Figure S4) and was able to achieve near-complete inhibition of constitutive Gli-
driven luciferase activity in Sufu-KO-LIGHT cells.  Although 1 demonstrated significant 
inhibition of Gli-driven luciferase activity in Shh-LIGHT2 and Sufu-KO-LIGHT cells, control 
studies revealed that 1 caused an unexpected increase in CMV-driven firefly luciferase activity 
in NIH-3T3 cells at relevant concentrations (Figure S5).  Because an increase in luciferase 
activity can be linked to ligand-based stabilization of the luciferase enzyme,55 we sought to 
validate the effect of 1 on Gli in orthogonal, non-luciferase-based assays.  To directly measure 
the effect of 1 on Gli target gene expression, we assessed levels of Gli1 in both Shh-LIGHT2 and 
Sufu-KO-LIGHT cells treated with 1 after 30 h by qPCR.  Co-incubation of varying 
concentrations of 1 with Shh-LIGHT2 cells stimulated with 200 nM SAG or Sufu-KO-LIGHT 
cells resulted in corresponding inhibition of Gli1 mRNA in both cell types (Figure 4A,B).  To 
examine activity in different cellular contexts, we measured the ability of 1 to inhibit Gli-
dependent differentiation of C3H10T1/2 mesenchymal stem cells to alkaline phosphatase (ALP)-
positive osteoblasts,56 which occurred at an IC50 of 45 ± 15 nM (versus 58 ± 32 nM for 
Vismodegib).  We also tested the activity of 1 against Gli-dependent proliferation of ASZ001 
basal cell carcinoma cells, and found that 1 inhibited mBCC proliferation with an IC50 of 0.16 ± 
0.44 µM (versus 2.0 ± 0.1 µM for Vismodegib) (Figure 4C,D).  Collectively, these observations 
place conformationally restricted dipeptide 1 in a select class of Smo-independent Gli inhibitors 
with nanomolar potency in diverse cell types.
PKC effectors can influence diverse cellular processes that intersect with Gli both up- 
and downstream of Smo.24,25,26,27  Previous studies have suggested that the PKC activator 3 acts 
on Hh signaling downstream of Smo, and by dual mechanisms dependent on and independent of 
MEK/ERK signaling.27  Given this connection, we sought to establish whether the MEK/ERK 
pathway contributed to the activity of compound 1.  To ascertain whether the activity of 1 
dependent on MEK signaling, we examined the effect of 1 in Gli-driven luciferase activity in the 
presence of the selective MEK inhibitor CI-1040 (6, 100 nM).57  In Shh-LIGHT2 cells, 1 
maintained an ability to inhibit Gli-driven luciferase activity with 200 nM SAG upon co-
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11
application of 100 nM 6 (Figure 4F and Figure S6).  Likewise, in Sufu-KO-LIGHT cells, 1 
retained the ability to inhibit Gli in the presence of 100 nM 6 (Figure 4G and Figure S6).  Taken 
together, these studies indicate that 1 can influence downstream Gli activity in a manner that 
does not require MEK signaling.  While further studies are required to address potential PKC-
independent effects of 1 at prolonged time periods, our findings provide further support for a 
PKC-Gli axis and illuminate significant new mechanisms to target oncogenic Gli activity.  
Despite the clinical success of Smo-targeting drugs, a growing number of cancers are 
associated with Gli activity that is insensitive to Smo antagonism.  In this study we investigated a 
diverse library of PKC effectors for their ability to regulate endogenous Gli activity at multiple 
points within the Hh pathway.  Our studies reveal structure-sensitive and highly potent effects of 
PKC agonists on Gli activity both up- and downstream of Smo.  These new connections are 
inherently sensitive to small molecule intervention and can be exploited to address disease-
specific dependencies.  Importantly, our strategy established the PKC effector 1 as an antagonist 
of Smo-independent Gli activity with equal potency to clinical Smo-targeting drugs, and a new 
agent to elucidate PKC-Gli crosstalk in Gli-driven cancers.
METHODS
Details of the experimental procedures are provided in the Supporting Information.  
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